Capricor Therapeutics (NASDAQ:CAPR) PT Raised to $15.00 at Oppenheimer
Capricor Therapeutics (NASDAQ:CAPR – Free Report) had its target price boosted by Oppenheimer from $14.00 to $15.00 in a research note published on Tuesday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. A number of other equities research analysts have also recently issued reports on CAPR. Maxim Group reaffirmed […]
20 Sep 08:10 · The Markets Daily